**
As fears mount over a potentially catastrophic Ebola outbreak, researchers are racing against time to develop three new vaccines targeting the Bundibugyo species of the virus. With nearly 250 fatalities reported and over 1,000 suspected cases in the Democratic Republic of Congo (DRC), health authorities are urging rapid action to avert a crisis reminiscent of the devastating West African outbreak from 2014 to 2016.
Rising Concerns Over Ebola Outbreak
The International Aids Vaccine Initiative (IAVI) is spearheading one of the vaccine projects, emphasizing the gravity of the situation. Dr Mark Feinberg, head of IAVI, warned that the current outbreak could evolve into one of the most severe on record, if not worse than the previous epidemic that saw nearly 29,000 infections and over 11,000 deaths. The outbreak’s emergence in conflict zones with limited healthcare infrastructure amplifies the urgency for effective countermeasures.
The Coalition for Epidemic Preparedness Innovations (CEPI) is backing all three vaccine development efforts, underscoring the critical nature of rapid vaccine deployment. “Every day counts in the race against this deadly disease,” stated Dr Richard Hatchett, CEPI’s CEO.
Vaccine Development Efforts
The three vaccines in development are being crafted by IAVI, Moderna, and the University of Oxford, each employing distinct technologies to stimulate an immune response against the Bundibugyo glycoprotein, a key target on the virus’s surface.
IAVI is modifying the existing Zaire Ebola vaccine, utilising a harmless, engineered virus to train the immune system. Preliminary tests in monkeys have shown promising results, offering nearly 100% protection. However, Feinberg noted that clinical trials for this vaccine could still take seven to nine months to commence, despite efforts to expedite the process.
In parallel, Moderna is leveraging its mRNA technology, previously used to combat COVID-19, to develop its Bundibugyo vaccine. “We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most,” asserted Stéphane Bancel, CEO of Moderna.
The University of Oxford is also advancing its own vaccine prototype, which is expected to enter clinical trials within two to three months, further contributing to the global response.
Challenges in Containing the Outbreak
The current outbreak is particularly challenging to manage due to its location in a conflict zone, which complicates both healthcare delivery and surveillance efforts. Médecins Sans Frontières (MSF) has described the situation as “deeply alarming,” noting that the number of cases has surged more rapidly than in previous outbreaks.
Vaccination against Ebola is complicated by the existence of multiple virus species. While a vaccine is already available for the Zaire strain, the Bundibugyo species has only been seen twice before, with no licensed vaccine currently available. This underscores the necessity for targeted vaccine development for each strain.
The three candidates under development aim to teach the immune system to recognise the Bundibugyo glycoprotein. IAVI’s approach uses a harmless virus, while both Moderna and Oxford’s vaccines employ mRNA technology to instruct cells to produce the glycoprotein, prompting an immune response.
The Path Ahead
Despite the advancements in vaccine research, the path to widespread vaccination remains fraught with challenges. Each technology may yield different levels of protection or require varying dosages, necessitating thorough clinical testing.
The World Health Organization (WHO) has echoed the need for a Bundibugyo vaccine to not only control the current epidemic but also to bolster preparedness for future outbreaks. Director-General Dr Tedros Adhanom Ghebreyesus emphasised the importance of such a development in mitigating the effects of potential future epidemics.
Why it Matters
The urgency surrounding the development of Ebola vaccines is not merely a matter of scientific interest but a critical public health imperative. With the spectre of a widespread outbreak looming, the swift mobilization of resources and collaborative international efforts could be the difference between containment and catastrophe. As the world grapples with the ongoing impacts of previous health crises, the lessons learned underscore the necessity for timely intervention and innovation in vaccine development to safeguard global health.
